• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Universe Pharmaceuticals INC Announces Strategic Partnership with Lian-Ou Health to Develop its Digital Marketing and Sales on E-Commerce Platforms

    3/30/22 8:00:00 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UPC alert in real time by email

    Ji'an, Jiangxi, China, March 30, 2022 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that the Company had entered into a strategic cooperation agreement (the "Agreement") with Lian-Ou Health Pharmaceutical (Guangzhou) Co., Ltd. ("Lian-Ou Health"), a high-tech company focusing on pharmaceuticals, technology, operation, sales, and services, to develop the Company's digital marketing and expand its sales channels on e-commerce platforms.

    Pursuant to the Agreement, Lian-Ou Health will serve as the exclusive partner for the Company's digital marketing efforts and as an authorized partner for the sales of the Company's products on e-commerce platforms until December 31, 2024. Both parties agreed to cooperate with each other on areas including product promotion, product development and support, and customer services by leveraging each other's resources and advantages. Both parties also agreed to provide training for the other party's employees to further strengthen their competitiveness.

    The strategic alliance with Lian-Ou Health is one of the Company's approaches to stay competitive with the fast-evolving digital economy in China and tackle the challenges associated with the COVID-19 pandemic by exploring solutions in digital marketing and sales. Moreover, the Company focuses on its current business lines and continuously innovates in developing digital marketing and sales on e-commerce platforms, which is expected to provide the Company a new opportunity to grow in the face of the changing market environment.

    Mr. Hanhui Li, Vice President of Lian-Ou Health, said, "As a practitioner of pharmaceutical Direct-To-Consumer ("DTC") digital marketing and sales strategy, Lian-Ou Health has been exploring marketing strategies to adapt to changes in the pharmaceutical market. In the future, Lian-Ou Health will integrate digital capabilities and marketing resources for the Company's digital transformation and work together to build the Company's image as a longevous enterprise with well-recognized brands."

    Mr. Baochang Liu, COO of Universe Pharmaceuticals INC, commented, "Cooperating with Lian-Ou Health will increase the Company's brand value and is also an important turning point for the Company toward the digital marketing track. With Lian-Ou Health's expertise, we will develop our digital marketing capabilities and further improve our brand recognition."

    Mr. Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC, commented, "The Company has always been deeply devoted to the traditional Chinese medicine market. We adhere to producing high-quality products and strive to enhance the brand recognition of our product ‘Bai Nian Dan' among middle-aged and elderly people. Recent changes in the macro-environment and consumer preferences drive the Company to empower its brands through digital marketing and sales on e-commerce platforms. Moving forward, we are confident that our strategic cooperation with Lian-Ou Health will help us achieve sustainable development in the long run."

    About Lian-Ou Health Pharmaceutical (Guangzhou) Co., Ltd.

    Lian-Ou Health is a high-tech company focusing on medical treatment, technology, operation, sales and services. Lian-Ou Health provides digital basic services for business customers in the medical and health industry, including digital marketing services, self-developed AI-assisted diagnosis and treatment system, private domain traffic operation SaaS system, and network clinic SaaS system, Lian-Ou Health aims to help digital upgrade, content upgrade and membership upgrade of medical and health industry. For more information, visit website at http://www.lian-ou.com/.

    About Universe Pharmaceuticals INC

    Universe Pharmaceuticals INC, headquartered in Ji'an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the Company's products are sold in 30 provinces of China. For more information, visit the Company's website at http://www.universe-pharmacy.com/.

    Forward-Looking Statements

    All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the SEC.

    For more information, please contact:

    Ascent Investors Relations LLC

    Tina Xiao

    President

    Phone: 917-609-0333

    Email: [email protected]



    Primary Logo

    Get the next $UPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:27:11 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:25:06 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:20:47 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure

    Ji'an, Jiangxi, China, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that all conditions to the implementation of its dual-class share structure have been satisfied and that its dual-class share structure will become effective on the Nasdaq Capital Market on February 13, 2026. In connection with the implementation of its dual-class share structure, the Company amended and restated its memorandum and articles of association and the Company's authorized share capital was changed to US$20,000 divided into 1,800,000,000 class A ordinary shares of pa

    2/11/26 4:05:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Universe Pharmaceuticals INC Announces Share Consolidation

    Jiangxi, China, March 20, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share consolidation of 40 ordinary shares with par value of US$0.28125 per share each in the Company's issued and unissued share capital into one (1) ordinary share with par value of US$11.25 (the "Share Consolidation"). As a result of the Share Consolidation, each 40 pre-consolidation ordinary shares outstanding will automatically combine and convert to one issued and outstanding ordinary share without any action on the part of the shareholders. Th

    3/20/25 8:30:00 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report

    Ji'an, Jiangxi, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the "Form 20-F") and that this matter serves as an additional basis for delisting the Company's securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1). The Com

    2/25/25 4:10:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    SEC Filings

    View All

    SEC Form 6-K filed by Universe Pharmaceuticals Inc.

    6-K - Universe Pharmaceuticals INC (0001809616) (Filer)

    2/11/26 4:06:12 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Universe Pharmaceuticals Inc.

    20-F - Universe Pharmaceuticals INC (0001809616) (Filer)

    1/28/26 7:34:16 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Universe Pharmaceuticals Inc.

    SCHEDULE 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)

    1/7/26 3:37:31 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Leadership Updates

    Live Leadership Updates

    View All

    Universe Pharmaceuticals INC Appoints Mr. Baochang Liu as Chief Operating Officer

    Ji'an, Jiangxi, China, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that the Company appointed Mr. Baochang Liu as its Chief Operating Officer, effective December 1, 2021. Mr. Baochang Liu has over 17 years of experience in pharmaceutical marketing. Mr. Baochang Liu has been working as the vice president of marketing and general manager of OTC department at China Shineway Pharmaceutical Group Ltd. since December 2019. Mr. Baochang Liu served as the general manager of OTC department at Chengdu Kanghong Pharmaceutical Group Co., Ltd. from November 2015 to December 2019. Prior

    12/15/21 4:30:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Universe Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)

    2/14/23 2:14:41 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Universe Pharmaceuticals Inc.

    SC 13G - Universe Pharmaceuticals INC (0001809616) (Subject)

    2/11/22 8:00:43 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Universe Pharmaceuticals Inc.

    SC 13G - Universe Pharmaceuticals INC (0001809616) (Subject)

    12/28/21 4:10:53 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care